U.S. General Merchandise and Department Stores Stock News

NasdaqGS:JBHT
NasdaqGS:JBHTTransportation

J.B. Hunt (JBHT) Stock Faces Rich P/E As EPS Recovery Challenges Bearish Narratives

J.B. Hunt Transport Services (JBHT) has reported Q2 2026 revenue of US$3.5 billion and basic EPS of US$1.91, against a backdrop where earnings over the last year are reported to have grown 21.8%. The company’s quarterly revenue has increased from US$2,928.2 million and EPS of US$1.32 in Q2 2025 to US$3,495.3 million and EPS of US$1.91 in Q2 2026. Over the same period, trailing net margin has moved up to 5.3% from 4.6% in the prior year. These shifts may encourage investors to examine how the...
NasdaqGS:NDAQ
NasdaqGS:NDAQCapital Markets

Nasdaq (NDAQ) Could Be 11% Undervalued As Earnings Expectations Build

Nasdaq (NDAQ) is drawing fresh attention as investors position ahead of its July 23 earnings report, with expectations for higher quarterly earnings and revenue, while mixed sentiment creates uncertainty around a potential beat or miss. See our latest analysis for Nasdaq. At a share price of $94.25, Nasdaq has seen a 7.69% 7 day share price return and a 6.37% 90 day share price return. The 1 year total shareholder return of 6.10% sits against a softer year to date share price return that is...
NasdaqGM:TMDX
NasdaqGM:TMDXMedical Equipment

TransMedics Group (TMDX) Stock Still Looks Below Fair Value After A 154% Run

After a mixed few years for shareholders, TransMedics Group stock now sits at around US$76 with a 5 year return of roughly 154%, and the current valuation checks suggest that, despite recent share price pressure, the stock still leans toward the cheaper side of the spectrum. Over 5 years, TransMedics Group has returned about 153.6%, which puts the recent 1 year and year to date share price declines in the context of a much stronger longer term run. The recent investment in Germany based PAD...
NYSE:TNK
NYSE:TNKOil and Gas

Teekay Tankers (TNK) Gains Value Stock Attention As Undervalued Case Comes Into Focus

Teekay Tankers (TNK) has been in focus after analysts highlighted the stock as a value play, pointing to valuation ratios and an earnings outlook that has attracted renewed attention from value-oriented investors. See our latest analysis for Teekay Tankers. Teekay Tankers' recent move to US$71.83 comes after a 7 day share price return of about 3.7% and a year to date share price return of roughly 39.5%. The 1 year total shareholder return of about 64.9% and very large 5 year total shareholder...
NYSE:CLVT
NYSE:CLVTProfessional Services

Clarivate (CLVT) Could Be 43% Undervalued After France Library Win

Clarivate (CLVT) has been selected by France’s Bibliographic Agency for Higher Education, Abes, to modernize the national academic library system covering more than 15 million records across 3,000 libraries, while management reaffirmed full year revenue guidance. See our latest analysis for Clarivate. Clarivate’s recent Abes win and its support for the U.S. Patent and Trademark Office’s AI assisted image search come as the stock shows short term momentum, with a 1 month share price return of...
NYSE:UNP
NYSE:UNPTransportation

Is Union Pacific (UNP) Fairly Valued With Merger Upside Priced In?

Union Pacific stock has delivered a 52.7% return over the past five years, and at around US$299 per share the valuation signals are now more finely balanced, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating the shares are roughly in line with fair value while earnings based multiples still screen as attractive. Over the last 5 years, a 52.7% return suggests Union Pacific has already rewarded long term holders. Fresh buyers need to think carefully about how much upside...
NYSE:DGX
NYSE:DGXHealthcare

The Bull Case For Quest Diagnostics (DGX) Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Quest Diagnostics Incorporated recently integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumors into Flatiron Health’s OncoEMR via a pilot with American Oncology Network and other community providers, giving 4,700 clinicians at 1,600 U.S. cancer care locations easier access to these tests within their existing electronic health record workflows. This move makes Quest the largest clinical reference lab to plug advanced oncology testing directly...
NYSE:ONON
NYSE:ONONLuxury

AppLovin Stock And 2 Fast Growing Insider Backed Tech Names

With inflation signals mixed across major economies, rate paths uncertain and trade policies in flux, many investors are looking for companies where insiders are strongly aligned with shareholders and where external expectations remain optimistic. The Fast Growing Stocks With High Insider Ownership screener focuses exactly on that combination, highlighting businesses where growth prospects are supported by both analyst and management outlooks. In this article, you will see three stocks from...
NYSE:HCI
NYSE:HCIInsurance

Does HCI Group’s Reaffirmed Dividend Reveal Its True Capital Allocation Priorities for Investors (HCI)?

HCI Group’s board has declared a regular quarterly cash dividend of US$0.40 per common share, payable on September 18, 2026, to shareholders of record as of August 21, 2026. This reaffirmed payout, alongside strong growth in premiums, earnings and book value per share, underscores management’s confidence in the insurer’s financial position. With the dividend reaffirmed, we’ll examine how this income commitment and recent analyst upgrades affect HCI Group’s evolving investment narrative. The...
NasdaqGS:XP
NasdaqGS:XPCapital Markets

XP (XP) After Its AI Procurement Shift Looks Undervalued Under The Main Narrative

XP (NasdaqGS:XP) is drawing fresh attention after XP Investimentos reported that over 99% of corporate spend now flows through an integrated, AI supported procurement platform. The shift is aimed at tighter cost control and supplier risk management. See our latest analysis for XP. XP's recent AI procurement update comes as the stock trades at US$16.68, with a 30 day share price return of 6.38%, a 90 day share price decline of 20.95%, and a 1 year total shareholder return decline of 5.82%...
NYSE:DHR
NYSE:DHRLife Sciences

Danaher (DHR) Stock Looks Reasonable Despite Rich Earnings Pricing

Danaher stock sits in an unusual valuation spot right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a meaningful discount, while earnings-based multiples lean the other way and flag the shares as expensive. Over the past 5 years, Danaher shares have declined 18%, which means long-term holders have not yet seen a clear payoff from staying invested. Recent news around Leica Biosystems’ planned acquisition of StatLab and new Alzheimer’s testing capabilities at...
NasdaqGS:HAS
NasdaqGS:HASLeisure

Hasbro (HAS) Lands Nintendo Zelda Toy Deal Ahead Of 2027 Film

Hasbro, ticker NasdaqGS:HAS, and Nintendo have agreed a multi year licensing partnership to produce The Legend of Zelda toys. The toy line is scheduled to launch in 2027 alongside the planned live action The Legend of Zelda film. The agreement extends Hasbro's relationship with Nintendo beyond existing franchises and adds a new entertainment linked product range. Hasbro has been building out its position in branded toys, games and collectibles, and this new Zelda partnership is part of...
NYSE:BA
NYSE:BAAerospace & Defense

Boeing (BA) Stock May Be Below Fair Value On MAX 7 Certification

Boeing stock has slipped about 7.2% over the past year, yet the valuation signals are split, with a Discounted Cash Flow (DCF) estimate pointing to meaningful upside while market multiples suggest the shares are not cheap. Boeing's share price is down 7.2% over the past year, which puts more focus on whether the current level already reflects its operational and regulatory challenges. Progress on 737 MAX certifications and production ramp ups can support future cash flow expectations, while...
NYSE:BABA
NYSE:BABAMultiline Retail

Alibaba Group Holding (BABA) Links Up With Apple Intelligence, Is It Still 20% Undervalued?

Alibaba Group Holding (NYSE:BABA) has been in focus after Chinese regulators approved Apple Intelligence for use in China, pairing Apple’s on device AI services with Alibaba’s Qwen models across multiple Apple platforms. See our latest analysis for Alibaba Group Holding. Recent moves in Alibaba Group Holding’s share price reflect that traders are reacting strongly to AI and regulatory headlines, with a 7 day share price return of 5.71% and a 1 year total shareholder return of 1.06%...
NasdaqGS:ECHO
NasdaqGS:ECHOMedia

EchoStar (ECHO) Stock Still May Be Below Fair Value On SpaceX Stake Buzz

EchoStar stock has delivered a very strong 378.5% return over the past three years, yet its valuation checks currently send mixed signals as the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market multiples lean the other way. Over three years, EchoStar has returned 378.5%. This makes the current pricing question more about how much of the story is already reflected in the share price. Recent analyst focus on the potential value of EchoStar's SpaceX...
NYSE:GNW
NYSE:GNWInsurance

Genworth Financial (GNW) CEO Leave Puts Valuation Back In Focus

Why Genworth Financial’s Leadership Change Matters for Shareholders Genworth Financial (GNW) recently announced that long-time President and CEO Tom McInerney is taking a temporary health-related leave of absence, with Chief Financial Officer Jerome Upton appointed as Interim President and CEO. For you as an investor, this type of leadership shift can influence how the market thinks about Genworth Financial’s future priorities, risk profile, and capital allocation. This is particularly...
NYSE:PFE
NYSE:PFEPharmaceuticals

Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer

Pfizer (PFE) is back in focus after the U.S. Food and Drug Administration approved PADCEV plus Keytruda as a platinum free neoadjuvant and adjuvant regimen for adult patients with muscle invasive bladder cancer. See our latest analysis for Pfizer. The latest FDA approval lands as Pfizer’s share price has been under pressure over longer periods, with a 90 day share price return that declined 8.78% but a 1 year total shareholder return of 9.43%. This suggests momentum is trying to rebuild from...
NYSE:BBWI
NYSE:BBWISpecialty Retail

Bath & Body Works (BBWI) Enters Brazil As The Undervalued Narrative Gets A Fresh Look

Bath & Body Works (BBWI) has just entered Brazil with its first store and a new digital destination in São Paulo, giving investors fresh context for thinking about the stock’s international growth ambitions. See our latest analysis for Bath & Body Works. For context, Bath & Body Works shares trade at US$21.12, with recent momentum skewing short term. The 1-day share price return is 2.23%, the 7-day return is 5.97% and the 90-day return is 8.81%, while the 1-year total shareholder return has...
NasdaqCM:SHAZ
NasdaqCM:SHAZIT

SharonAI Holdings (SHAZ) Stock Looks Fully Priced After A Very Large Run

SharonAI Holdings has delivered a very large 1 year return, yet its valuation checks and current market multiples point to a stock that leans expensive rather than clearly cheap. Over the last 12 months, SharonAI Holdings has returned about 7.7x, which puts extra pressure on today’s price to be backed by durable cash flow and earnings quality. Expectations that the company can translate its business model into consistent, scalable cash generation may support the current share price. However,...
NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

How Do Tempus AI’s (TEM) NHS Prostate Results Shape Its Clinical Credibility Narrative?

Tempus AI recently highlighted results from the Articulate Pro study in Nature Digital Medicine, showing that the Paige Prostate Suite AI improved diagnostic consistency, sped up prostate biopsy reporting, and reduced laboratory workloads within the UK National Health Service. An important insight from the study is that AI-assisted review led to diagnosis or Grade Group updates in 5% of cases, with 1.3% potentially altering clinical management, underscoring how AI can meaningfully influence...
NYSE:ADC
NYSE:ADCRetail REITs

How Investors Are Reacting To Agree Realty (ADC) Raising Its Monthly Dividend Payout

In July 2026, Agree Realty Corporation’s board declared a higher monthly cash dividend of US$0.267 per common share, implying an annualized US$3.204 and a 4.3% increase from the third quarter of 2025, alongside a monthly US$0.08854 dividend per Series A preferred depositary share, both paid in August 2026 to July record holders. This step-up in common and preferred payouts highlights management’s willingness to return more cash to investors, underscoring confidence in the REIT’s recurring...
NasdaqGS:NXPI
NasdaqGS:NXPISemiconductor

NXP Semiconductors (NXPI) Is Down 6.8% After AI Capex Jitters Hit Chipmakers’ Margins Narrative

In recent days, NXP Semiconductors has been caught up in a broad semiconductor pullback as investors reacted to higher capital expenditure plans and margin pressures linked to scaling AI manufacturing capacity across the industry. This sector-driven swing highlights how NXP’s valuation narrative, previously anchored in automotive and communications demand, can quickly be reshaped by changing expectations around industry-wide investment costs and profitability. We’ll now examine how this...
NYSEAM:STXS
NYSEAM:STXSMedical Equipment

Stereotaxis (STXS) Could Be 53% Undervalued As Shelf Filings Raise Dilution Questions

Stereotaxis (STXS) recently filed two shelf registrations that together cover up to about $205.3 million of common equity, highlighting potential future capital raises that could affect dilution and investor sentiment toward the stock. See our latest analysis for Stereotaxis. The recent shelf registrations arrive during a weaker patch for Stereotaxis, with the stock closing at US$1.65 and recording a 30 day share price return down 9.34%, alongside a 1 year total shareholder return down 30.67%...
NasdaqGS:TSEM
NasdaqGS:TSEMSemiconductor

Tower Semiconductor (TSEM) Stock Looks Fully Priced On Earnings Yet Backed By Growth

Tower Semiconductor stock has delivered very strong returns over the past few years, yet its valuation checks lean expensive, which raises the question of how much of the growth story is already reflected in the current price. Over the past 5 years, Tower Semiconductor has returned about 7.9x, which puts the recent share price performance at the center of any valuation discussion. Plans for a US$3b expansion in Japan focused on silicon photonics and AI related chip production can support...